Please login to the form below

Not currently logged in
Email:
Password:

Signifor

This page shows the latest Signifor news and features for those working in and with pharma, biotech and healthcare.

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA. Signifor LAR shows superior efficiency to older treatments. ... Signifor LAR needs to be given just once a month, allowing it to compete head-to-head with its rivals in this setting.

Latest news

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    Novartis gets EU nod for rare disease drug Signifor. Long-acting formulation of drug approved for growth disorder acromegaly. ... This first approval of Signifor in acromegaly marks a much needed advance in the treatment of this rare disease.".

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    A phase III trial of Novartis' somatostatin analogue Signifor has suggested it could be effective for the growth hormone disorder acromegaly. ... The shorter-acting, subcutaneous form of Signifor was approved in 2012, and to date Novartis has not broken

  • Novartis cancer chief Hoppenot leaves for top job at Incyte Novartis cancer chief Hoppenot leaves for top job at Incyte

    During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's

  • Year-end FDA approvals for Novartis, GSK drugs Year-end FDA approvals for Novartis, GSK drugs

    Year-end FDA approvals for Novartis, GSK drugs. Agency gives go-ahead to Cushing’ s disease treatment Signifor and raxibacumab for inhalational anthrax. ... In addition to Cushing's syndrome, Signifor is also being developed to treat the rare endocrine

  • Novartis' heart failure drug serelaxin meets targets Novartis' heart failure drug serelaxin meets targets

    Novartis' heart failure drug serelaxin meets targets. And FDA committee backs Signifor for Cushing's disease. ... If the FDA concurs with that view, somatostatin analogue Signifor could become the first approved treatment for Cushing's in the US.

More from news
Approximately 5 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics